Related references
Note: Only part of the references are listed.Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan et al.
INVESTIGATIONAL NEW DRUGS (2020)
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers
Federico De Marchi et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens
Li-Hui Tseng et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations
Laura N. Toth et al.
HUMAN PATHOLOGY (2018)
IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer
Jiang-jiang Li et al.
MOLECULAR ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
Iwona Lugowska et al.
JOURNAL OF CANCER (2018)
Effect Sizes of Somatic Mutations in Cancer
Vincent L. Cannataro et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5
Bingdi Yan et al.
OPEN BIOLOGY (2018)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
A New Functional IDH2 Genetic Variant Is Associated With the Risk of Lung Cancer
Jiangjiang Li et al.
MOLECULAR CARCINOGENESIS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical mutational profiling of 1006 lung cancers by next generation sequencing
Peter B. Illei et al.
ONCOTARGET (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
IDH mutations in cancer and progress toward development of targeted therapeutics
L. Dang et al.
ANNALS OF ONCOLOGY (2016)
Clinical Mutational Profiling of Bone Metastases of Lung and Colon Carcinoma and Malignant Melanoma Using Next-Generation Sequencing
Gang Zheng et al.
CANCER CYTOPATHOLOGY (2016)
CDX-2 Expression in Primary Lung Adenocarcinoma
Morgan L. Cowan et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers
Lisa Haley et al.
MODERN PATHOLOGY (2015)
Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
Nicholas McGranahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
Liang Xia et al.
ONCOTARGET (2015)
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase.
Hongdo Do et al.
Oncotarget (2015)
Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
Ming-Tseh Lin et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
Remco J. Molenaar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing
Guoli Chen et al.
MOLECULAR DIAGNOSIS & THERAPY (2014)
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Helga Thorvaldsdottir et al.
BRIEFINGS IN BIOINFORMATICS (2013)
Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non-Small Cell Lung Cancer
Nan Sun et al.
CLINICAL CANCER RESEARCH (2013)
Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data
David A. Gutman et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2013)
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp et al.
HUMAN PATHOLOGY (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (vol 462, pg 739, 2010)
Lenny Dang et al.
NATURE (2010)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
